Vectibix News and Research

RSS
Vectibix is a human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Vectibix binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth. Also called ABX-EGF and panitumumab.
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience completes $8.5 million Series A financing

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen receives EC approval to extend therapeutic indications for Vectibix

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recommendations on new cancer drug review process fall short in several ways: CCAC

Recommendations on new cancer drug review process fall short in several ways: CCAC

Amgen acquires Bergamo, expands operations in Brazil

Amgen acquires Bergamo, expands operations in Brazil

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer